Since we observe that SETD2 deficiency is associated with the appearance of free ATG12, as well as the expression additional ATG12-containing complexes, and an overall increase in total ATG12 protein expression levels, we decided to investigate whether ATG12 gene expression levels, as well as the expression of the gene, i.e., SETD2, which product is causing the global increase in ATG12 expression levels, could be used as survival prognostic factors for ccRCC patients. Here, SETD2 is linked to nonpapillary renal cell carcinoma.